Gene expression signatures: biomarkers toward diagnosing multiple sclerosis

Identification of biomarkers contributing to disease diagnosis, classification or prognosis could be of considerable utility. For example, primary methods to diagnose multiple sclerosis (MS) include magnetic resonance imaging and detection of immunological abnormalities in cerebrospinal fluid. We determined whether gene-expression differences in blood discriminated MS subjects from comparator groups, and identified panels of ratios that performed with varying degrees of accuracy depending upon complexity of comparator groups. High levels of overall accuracy were achieved by comparing MS with homogeneous comparator groups. Overall accuracy was compromised when MS was compared with a heterogeneous comparator group. Results, validated in independent cohorts, indicate that gene-expression differences in blood accurately exclude or include a diagnosis of MS and suggest that these approaches may provide clinically useful prediction of MS.

[1]  C. Weyand,et al.  Rejuvenating the immune system in rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[2]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[3]  Marco Rovaris,et al.  MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study , 2007, The Lancet Neurology.

[4]  P. Gregersen,et al.  Fine mapping the phenotype in autoimmune disease: the promise and pitfalls of DNA microarray technologies , 2003, Genes and Immunity.

[5]  Javed Khan,et al.  Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. , 2003, Human molecular genetics.

[6]  N. Olsen,et al.  Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. , 2005, Arthritis and rheumatism.

[7]  Guillermo Izquierdo,et al.  Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis , 2008, Proceedings of the National Academy of Sciences.

[8]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[9]  Yu Shyr,et al.  Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. , 2005, Human molecular genetics.

[10]  M. Meisler,et al.  TSRC1, a widely expressed gene containing seven thrombospondin type I repeats. , 2003, Gene.

[11]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[12]  Robert Zivadinov,et al.  New MRI criteria in the diagnosis of multiple sclerosis , 2007, The Lancet Neurology.

[13]  S. Sadiq,et al.  Disease Biomarkers in Multiple Sclerosis , 2012, Molecular Diagnosis & Therapy.

[14]  Bernhard Hemmer,et al.  Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis , 2010, Journal of Neuroimmunology.

[15]  N. Butowski Immunostimulants for malignant gliomas. , 2010, Neurosurgery clinics of North America.

[16]  S. Sadiq,et al.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. , 2009, Molecular diagnosis & therapy.

[17]  Cindy L Vnencak-Jones,et al.  Identification of molecular biomarkers for multiple sclerosis. , 2007, The Journal of molecular diagnostics : JMD.

[18]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[19]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[20]  B. Scheithauer,et al.  DNA microarrays , 2005, Endocrine.

[21]  John Quackenbush Microarray analysis and tumor classification. , 2006, The New England journal of medicine.

[22]  Rainer Spang,et al.  Microarray Based Diagnosis Profits from Better Documentation of Gene Expression Signatures , 2008, PLoS Comput. Biol..

[23]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[24]  Thomas M. Aune,et al.  Cutting Edge: Molecular Portrait of Human Autoimmune Disease1 , 2002, The Journal of Immunology.

[25]  K. Maas,et al.  Defective ATM‐p53–mediated apoptotic pathway in multiple sclerosis , 2005, Annals of neurology.

[26]  T. Aune,et al.  Identification of gene expression signatures in autoimmune disease without the influence of familial resemblance. , 2006, Human molecular genetics.

[27]  H. Abdi The Bonferonni and Šidák Corrections for Multiple Comparisons , 2006 .

[28]  Lawrence Steinman,et al.  T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.

[29]  Jan Hillert,et al.  Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? , 2010, Neurobiology of Disease.

[30]  P. Schwartzberg,et al.  Tec kinases regulate T‐lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk , 2009, Immunological reviews.

[31]  Hans-Peter Lenhof,et al.  Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls , 2009, PloS one.

[32]  C. Weyand,et al.  Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis , 2009, The Journal of experimental medicine.